it started from an “Apricot”
・Misao Tomiyama, a representative employee and partner of Kotobuki Shokai, a limited partnership established in 1931, receives a license from Nagano Prefecture to manufacture and sell pharmaceuticals at the company’s Toyono Plant in Nagano City and establishes Kotobuki Seiyakusho.
The limited partnership, Kotobuki Shokai, had produced apricot jam, and produced apricot kernel water from apricot seeds, which were mostly waste1).
The company also manufactures and sells medicines derived from crude drugs produced in Nagano Prefecture (Senega syrup, lotus extract, etc.).
By cultivating herbal medicines in Nagano Prefecture, the company will also contribute to the preservation of the natural environment and the creation of job opportunities in Nagano Prefecture2).
Both 1) and 2) are based on the SDGs.
Apricot kernel water
・Kotobuki Pharmaceutical Co., Ltd. was registered as a corporation.
・Misao Tomiyama took office as president.
・Moved the head office to 6351, Sakaki, Sakaki-machi.
・Began production and marketing of a synthetic drug, buformin hydrochloride.
・President Tomiyama was awarded the Prime Minister’s Commendation.
Completion of the first stage construction of Research Laboratory.
・Our research paper published for the first time in Chemical & Pharmaceutical Bulletin.
SGLT2 Inhibitor for Treatment of Type 2 Diabetes(Joint development with Astellas Pharma Inc.), in Japan.
Selective SGLT2 Inhibitor “Suglat Tablets 25mg, 50mg (Suglat, Ipragliflozin L-Proline)”
Drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor “SUJANU Combination Tablets (SUJANU, Sitagliptin phosphate hydrate, Ipragliflozin L-Proline)”
・Approved for manufacturing and sales in Japan, and the drug price is listed and released.
FLT3 Inhibitor “XOSPATA 40mg Tablets (XOSPATA, Gilteritinib)”
・Relocation of Tokyo Office.
・Released “Kawara OD Tablet” in Japan.